Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

That's because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood ...

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

As a potential strike of Canada Post workers looms, the Crown corporation says it its “operating as normal” while negotiations with the union continue. If a strike does go ahead, at least one ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...